Xencor (XNCR) closed at $37.09 on November 13, 2026, down 2.7% from the previous close, on volume of 898,455 shares (30-day average 1,625,838).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Call Spread | 20-Nov-2630 : 40 C | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
BrightSpring, Centene stand out as healthcare's most persistent Strong Buys
Seeking Alpha News (Thu, 12-Nov 7:38 AM ET)
Canaccord Genuity Keeps Their Buy Rating on Xencor (XNCR)
TipRanks (Tue, 10-Nov 7:29 AM ET)
Business Wire (Mon, 9-Nov 8:01 AM ET)
Xencor Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:01 PM ET)
Defining Moments in the Race for Biotech Breakthroughs
Globe Newswire (Mon, 26-Oct 10:44 AM ET)
Market Chameleon (Mon, 26-Oct 6:25 AM ET)
Business Wire (Sun, 25-Oct 4:35 AM ET)
Business Wire (Mon, 19-Oct 7:01 AM ET)
Market Chameleon (Mon, 20-Jul 7:06 AM ET)
XmAb942 and XmAb412 Set New Benchmarks in Autoimmune Disease Therapy, Xencor Reports at DDW
Market Chameleon (Mon, 4-May 5:23 AM ET)
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Xencor trades on the NASDAQ stock market under the symbol XNCR.
As of November 13, 2026, XNCR stock price declined to $37.09 with 898,455 million shares trading.
XNCR has a beta of -0.21, meaning it tends to be less sensitive to market movements. XNCR has a correlation of 0.00 to the broad based SPY ETF.
XNCR has a market cap of $2.76 billion. This is considered a Mid Cap stock.
Last quarter Xencor reported $117 million in Revenue and $.50 earnings per share. This beat revenue expectation by $53 million and exceeded earnings estimates by $.84.
In the last 3 years, XNCR traded as high as $40.60 and as low as $6.92.
The top ETF exchange traded funds that XNCR belongs to (by Net Assets): IJR, IWM, VTI, XBI, IWN.
XNCR has outperformed the market in the last year with a price return of +165.1% while the SPY ETF gained +13.4%. XNCR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +61.3% and +24.4%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
XNCR support price is $36.45 and resistance is $39.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XNCR shares will trade within this expected range on the day.
